Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Daniel Ahn, Michelle Sidel, Laura Panattoni, Naomi Sacks, Jennifer Hernandez & Reginald Villacorta. (2022) Real-World Outcomes in Patients with First-Line and Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma. Future Oncology 18:30, pages 3419-3433.
Read now
Read now
Articles from other publishers (5)
Dharmindra Dulal, Andrew Boring, David Terrero, Tiffany Johnson, Amit K. Tiwari & Dayanidhi Raman. (2023) Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints. Cancers 15:10, pages 2774.
Crossref
Crossref
Jia Hu, Zhuomiao Ye, Zhe Xu, Zhinan Hao & Yongjun Wang. (2022) Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States. Frontiers in Public Health 10.
Crossref
Crossref
Yang Liu, Hongyu Hao, Lin Kang, Guona Zheng, Xiaowan Guo, Bingjie Li, Huanfen Zhao & Han Hao. (2022) Construction of a novel necroptosis-related lncRNA signature for prognosis prediction in esophageal cancer. BMC Gastroenterology 22:1.
Crossref
Crossref
Mei Zhan, Ting Xu, Hanrui Zheng & Zhiyao He. (2022) Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study. Frontiers in Public Health 10.
Crossref
Crossref
晓雅 李. (2021) Research Progress of PD-1/PD-L1 Inhibitors in Neoimmunoadjuvant Therapy of Esophageal Cancer. Advances in Clinical Medicine 11:11, pages 5106-5111.
Crossref
Crossref